| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EVI2A |
| Uniprot No | P22794 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-236aa |
| 氨基酸序列 | SPGTKANYTRLWANSTSSWDSVIQNKTGRNQNENINTNPITPEVDYKGNSTNMPETSHIVALTSKSEQELYIPSVVSNSPSTVQSIENTSKSHGEIFKKDVCAENNNNMAMLICLIIIAVLFLICTFLFLSTVVLANKVSSLRRSKQVGKRQPRSNGDFLASGLWPAESDTWKRTKQLTGPNLVMQSTGVLTATRERKDEEGTEKLTNKQIG |
| 分子量 | 49.06 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人EVI2A蛋白的3篇参考文献示例(基于公开研究方向和潜在研究方向构建，若需真实文献建议通过学术数据库检索)：
1. **标题**：*"Cloning and expression of recombinant human EVI2A protein in leukemia-associated signaling studies"*
**作者**：Zhang Y, et al.
**摘要**：研究团队通过原核表达系统成功克隆并纯化了重组人EVI2A蛋白，进一步分析了其在白血病细胞系中调控Ras/MAPK信号通路的潜在功能，发现其可能作为AML的潜在生物标志物。
2. **标题**：*"Structural characterization of EVI2A protein and its interaction with neurofibromin"*
**作者**：Thompson R, Buchberg AM.
**摘要**：利用哺乳动物表达系统重组表达EVI2A蛋白，结合X射线晶体学解析其结构，揭示了EVI2A与NF1基因产物神经纤维蛋白的结合位点，为神经纤维瘤病与白血病的关联机制提供结构基础。
3. **标题**：*"Development of a recombinant EVI2A-based ELISA assay for autoimmune disease diagnosis"*
**作者**：Lee S, et al.
**摘要**：通过杆状病毒-昆虫细胞系统高效表达重组EVI2A蛋白，并建立特异性ELISA检测方法，验证其在系统性红斑狼疮(SLE)患者血清中的自身抗体识别能力，展示其临床应用潜力。
注：以上文献为基于EVI2A相关研究的合理推测，若需实际文献，建议查阅PubMed或SciFinder数据库。
Recombinant human EVI2A (Ecotropic Viral Integration Site 2A) protein is derived from the EVI2A gene, located on chromosome 17q11.2 near the neurofibromatosis type 1 (NF1) gene. Initially identified as a common retroviral integration site in murine leukemia models, EVI2A encodes a transmembrane protein implicated in cellular processes such as proliferation, differentiation, and immune regulation. Structurally, EVI2A contains leucine-rich repeats and immunoglobulin-like domains, suggesting roles in protein-protein interactions and signal transduction. Its expression is detected in hematopoietic cells, certain cancers, and immune tissues, linking it to malignancies like leukemia and neurofibromatosis-associated tumors.
Recombinant EVI2A is typically produced using prokaryotic or eukaryotic expression systems (e.g., E. coli, mammalian cells) to ensure proper folding and post-translational modifications. This engineered protein facilitates studies on its biological functions, including its potential as an oncogenic driver or modulator of immune responses. Researchers utilize it to investigate EVI2A’s interactions with signaling pathways, such as RAS/MAPK or PI3K-AKT, and its role in tumor microenvironments. Additionally, it serves as a reagent for antibody development, diagnostic assays, and exploring therapeutic targets. Despite limited mechanistic understanding, EVI2A’s association with disease progression and stem cell regulation makes it a compelling subject for translational research.
×
